Associations of serum sclerostin levels with body composition, pulmonary function, and exacerbations in COPD patients

In COPD, the bronchial epithelium shows a pathologically activated Wnt pathway. Sclerostin (SOST) is a secreted glycoprotein that is associated with bone metabolism and blocks the Wnt pathway. We hypothesized that low sclerostin levels might be associated with lung function and COPD exacerbations in...

Full description

Saved in:
Bibliographic Details
Published in:Pulmonology 2022-08
Main Authors: Amado, C.A., García-Unzueta, M., Agüero, J., Martín-Audera, P., Fueyo, P., Lavín, B.A., Guerra, A.R., Muñoz, P., Tello, S., Berja, A., Casanova, C.
Format: Article
Language:English
Subjects:
COPD
Exacerbation
Sarcopenia
Sclerostin
WNT pathway
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In COPD, the bronchial epithelium shows a pathologically activated Wnt pathway. Sclerostin (SOST) is a secreted glycoprotein that is associated with bone metabolism and blocks the Wnt pathway. We hypothesized that low sclerostin levels might be associated with lung function and COPD exacerbations in patients. We studied 139 outpatients with stable COPD and normal kidney function. We assessed the serum levels of SOST and bone metabolism parameters, body composition, clinical characteristics and lung function at baseline. We followed the patients prospectively for 12 months after enrolment. Moderate exacerbations and hospital admissions were recorded during follow-up. The serum SOST levels were 23.98±7.6 pmol/l (men: 25.5±7.7 pmol/l, women: 20.3±5.9 pmol/l (p 
ISSN:2531-0437
2531-0437
DOI:10.1016/j.pulmoe.2022.06.003